Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame	Description
Primary	The incidence of grade II to IV aGVHD	Day 0 to Day 100 after transplantation	The primary endpoint of the study will be the development of grade II to IV aGVHD in the first 100 days post-transplant. Acute GVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria.
Secondary	Incidence of Neutrophil Engraftment	Day 0 to Day 42 after transplantation	The cumulative incidence of neutrophil engraftment. Neutrophil engraftment is defined as the first of three consecutive days with an absolute neutrophil count (ANC) ≥0.5 × 10⁹/L.
Secondary	Incidence of Platelet Engraftment	Day 0 to Day 60 after transplantation	The cumulative incidence of platelet engraftment without platelet transfusion support.
Secondary	Time to Platelet Engraftment	From transplantation until platelet engraftment or Day 365 after transplantation, whichever occurs first	Time from transplantation to platelet engraftment, defined as the first of seven consecutive days with a platelet count ≥20 × 10⁹/L without platelet transfusion.
Secondary	Cumulative Incidence of Platelet recovery	Day 0 to Day 120 after transplantation	The cumulative incidence of platelet count ≥50 × 10⁹/L without platelet transfusion.
Secondary	Incidence of Grade III-IV Acute GVHD	Day 0 to Day 100 after transplantation	The proportion of participants who develop Grade III-IV acute graft-versus-host disease (aGVHD).
Secondary	Incidence of Chronic GVHD	Day 0 to Day 365 after transplantation	The proportion of participants who develop chronic graft-versus-host disease (cGVHD), diagnosed according to standard diagnostic criteria.
Secondary	Immune Reconstitution	At 1, 2, 3, 6, and 12 months after transplantation	Immune reconstitution assessed by serum immunoglobulin levels (IgA, IgG, and IgM) and lymphocyte subset analysis, including total lymphocytes, T cells, CD4⁺ T cells, CD8⁺ T cells, regulatory T cells, B cells, NK cells, activated CD4⁺ T cells, activated CD8⁺ T cells, CD8⁺ effector memory T cells, CD8⁺ effector T cells, regulatory B cells, naïve B cells, and memory B cells.
Secondary	Transplant-Related Mortality (TRM)	Day 0 to Day 180 after transplantation	The proportion of participants who die from causes other than disease progression or relapse following transplantation.
Secondary	Incidence of Infection	Day 0 to Day 365 after transplantation	The proportion of participants who develop documented bacterial, viral, or fungal infections after transplantation.
Secondary	Disease-Free Survival (DFS)	Day 0 to Day 365 after transplantation	Disease-free survival is defined as the time from transplantation to disease relapse, death from any cause, or the last follow-up, whichever occurs first.
Secondary	Overall Survival (OS)	Day 0 to Day 365 after transplantation	Overall survival is defined as the time from transplantation to death from any cause or the last follow-up.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07885982/registered

API reference For AI assistants